Long-term clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis stratified by baseline MRI and c-reactive protein status
Zochling J, Robinson PC, Maksymowych WP, Gensler LS, Rudwaleit M, Hoepken B, Bauer L, Kumke T, Kim M, Deodhar A (2023)
Internal Medicine Journal 53(Suppl. 1): 25.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Zochling, Jane;
Robinson, Philip C.;
Maksymowych, Walter P.;
Gensler, Lianne S.;
Rudwaleit, MartinUniBi;
Hoepken, Bengt;
Bauer, Lars;
Kumke, Thomas;
Kim, Mindy;
Deodhar, Atul
Einrichtung
Erscheinungsjahr
2023
Serien- oder Zeitschriftentitel
Internal Medicine Journal
Band
53
Ausgabe
Suppl. 1
Seite(n)
25
Konferenz
Australian Rheumatology Association (ARA) 63rd Annual Scientific Meeting
Konferenzort
Hobart, Tasmania
Konferenzdatum
2023-05-06 – 2023-05-09
ISSN
1444-0903
eISSN
1445-5994
Page URI
https://pub.uni-bielefeld.de/record/2982790
Zitieren
Zochling J, Robinson PC, Maksymowych WP, et al. Long-term clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis stratified by baseline MRI and c-reactive protein status. Internal Medicine Journal. 2023;53(Suppl. 1):25.
Zochling, J., Robinson, P. C., Maksymowych, W. P., Gensler, L. S., Rudwaleit, M., Hoepken, B., Bauer, L., et al. (2023). Long-term clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis stratified by baseline MRI and c-reactive protein status. Internal Medicine Journal, 53(Suppl. 1), 25. https://doi.org/10.1111/imj.16057
Zochling, Jane, Robinson, Philip C., Maksymowych, Walter P., Gensler, Lianne S., Rudwaleit, Martin, Hoepken, Bengt, Bauer, Lars, Kumke, Thomas, Kim, Mindy, and Deodhar, Atul. 2023. “Long-term clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis stratified by baseline MRI and c-reactive protein status”, Internal Medicine Journal, 53 (Suppl. 1): 25.
Zochling, J., Robinson, P. C., Maksymowych, W. P., Gensler, L. S., Rudwaleit, M., Hoepken, B., Bauer, L., Kumke, T., Kim, M., and Deodhar, A. (2023). Long-term clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis stratified by baseline MRI and c-reactive protein status. Internal Medicine Journal 53, 25.
Zochling, J., et al., 2023. Long-term clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis stratified by baseline MRI and c-reactive protein status. Internal Medicine Journal, 53(Suppl. 1), p 25.
J. Zochling, et al., “Long-term clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis stratified by baseline MRI and c-reactive protein status”, Internal Medicine Journal, vol. 53, 2023, pp. 25.
Zochling, J., Robinson, P.C., Maksymowych, W.P., Gensler, L.S., Rudwaleit, M., Hoepken, B., Bauer, L., Kumke, T., Kim, M., Deodhar, A.: Long-term clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis stratified by baseline MRI and c-reactive protein status. Internal Medicine Journal. 53, 25 (2023).
Zochling, Jane, Robinson, Philip C., Maksymowych, Walter P., Gensler, Lianne S., Rudwaleit, Martin, Hoepken, Bengt, Bauer, Lars, Kumke, Thomas, Kim, Mindy, and Deodhar, Atul. “Long-term clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis stratified by baseline MRI and c-reactive protein status”. Internal Medicine Journal 53.Suppl. 1 (2023): 25.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar